Prescription drug · ANDA
Cholestyramine for Oral Suspension NDC 62135-937
Cholestyramine 4 g/5.7g · Powder · Oral · Chartwell RX, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 62135-937-54 | 6213509375462135093754 | 239.4 g in 1 CAN (62135-937-54)Marketed from Jan 3, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cholestyramine for Oral Suspension
- Generic name (nonproprietary)
- cholestyramine for oral suspension
- Active ingredients
- Cholestyramine — 4 g/5.7g
- Dosage form
- Powder
- Route
- Oral
- Labeler
- Chartwell RX, LLCNDC labeler code 62135
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 074562
- Marketing start
- Listing expires
- Other FDA classes
- Bile-acid Binding Activity (Mechanism)
- Identifiers
- Product ID 62135-937_f1d8692b-deb3-d55f-e053-2a95a90ae615SPL ID f1d8692b-deb3-d55f-e053-2a95a90ae615SPL set ID 80db0042-0c05-4509-8a6b-fa9f4783629aRxCUI 848943, 1801279UNII 4B33BGI082UPC 0362135008567, 0362135937546
- Pharmacologic class
- Bile Acid Sequestrant
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N462135093754followed by a unit qualifier and the quantityPackage 62135-0937-54. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE 1) Cholestyramine is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and co…
Excerpt only. Read the full label for complete information.
About NDC 62135-937
- What is NDC 62135-937?
- 62135-937 is the product NDC for Cholestyramine for Oral Suspension, Cholestyramine 4 g/5.7g powder, listed with the FDA by Chartwell RX, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Cholestyramine for Oral Suspension.
- What is the active ingredient?
- Cholestyramine.
- Who is the labeler?
- Chartwell RX, LLC, NDC labeler code 62135. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Cholestyramine for Oral Suspension?
- 1 other product NDC are listed under this name. See all Cholestyramine for Oral Suspension NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Cholestyramine for Oral Suspension products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Cholestyramine for Oral Suspension | Cholestyramine 4 g/9g | PowderOral | Chartwell RX, LLC | 62135-008 | 62135-0008-56 |